Palvella Therapeutics (PVLA) Short term Debt (2013 - 2014)
Palvella Therapeutics' (PVLA) quarterly Short term Debt came in at $1.3 million in Q4 2014, up 515.33% year-on-year from $206490.0 in Q4 2013, and up 36474.7% on a QoQ basis from $3474.0 in Q3 2014.
Palvella Therapeutics (PVLA) Short term Debt (2013 - 2014) Analysis & Trends
Palvella Therapeutics (PVLA) has 2 years of Short term Debt data on file, last reported at $1.3 million in Q4 2014.
- On a quarterly basis, Short term Debt rose 515.33% year-over-year to $1.3 million in Q4 2014; TTM through Dec 2014 was $1.3 million, a 515.33% increase from a year earlier, with the FY2014 full-year figure at $1.3 million, up 515.33% from the prior year.
- Short term Debt for Q4 2014 stood at $1.3 million, up from $3474.0 in the prior quarter.
- Over the last five years, Short term Debt for PVLA reached as high as $1.3 million in Q4 2014 and fell as low as $474.0 in Q2 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Palvella Therapeutics | 1.84 Bn | 1.57 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 1.27 Mn |
| Sep 30, 2014 | 3,474.00 |
| Jun 30, 2014 | 474.00 |
| Dec 31, 2013 | 206,490.00 |